Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincenza Conteduca

Showing results (81-90 of 157) with videos related to

Pageof 16
Sort By:
Expert Opinion on Pharmacotherapy|August 14, 2020
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancerAmelia Altavilla, Chiara Casadei, Cristian Lolli, et al.
FEBS Open Bio|April 4, 2025
Adenosine A<sub>3</sub> receptor antagonists as anti-tumor treatment in human prostate cancer: an in vitro studyMaria Beatrice Morelli, Andrea Spinaci, Cui Chang, et al.
Molecular Diagnosis & Therapy|March 30, 2016
Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate CancerVincenza Conteduca, Simon J Crabb, Emanuela Scarpi, et al.
Scientific Reports|October 20, 2018
Plasma androgen receptor and serum chromogranin A in advanced prostate cancerVincenza Conteduca, Emanuela Scarpi, Samanta Salvi, et al.
World Journal of Urology|October 9, 2025
The prostatic inflammation score and risk of biochemical recurrence following radical prostatectomyFrancesco Guzzi, Ugo Giovanni Falagario, Angelo Cormio, et al.
Frontiers in Oncology|October 19, 2020
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell TumorsGiuseppe Schepisi, Vincenza Conteduca, Chiara Casadei, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2019
Clinical features of neuroendocrine prostate cancerVincenza Conteduca, Clara Oromendia, Kenneth W Eng, et al.
The Prostate|April 22, 2017
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abirateroneVincenza Conteduca, Orazio Caffo, Cristian Lolli, et al.
Plos One|July 20, 2016
Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate CancerVincenza Conteduca, Simon J Crabb, Robert J Jones, et al.
Oncotarget|July 14, 2016
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinibCristian Lolli, Umberto Basso, Lisa Derosa, et al.
Pageof 16

Showing results (81-90 of 157) with videos related to

Sort By:
Pageof 16
Expert Opinion on Pharmacotherapy|August 14, 2020
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancerAmelia Altavilla, Chiara Casadei, Cristian Lolli, et al.
FEBS Open Bio|April 4, 2025
Adenosine A<sub>3</sub> receptor antagonists as anti-tumor treatment in human prostate cancer: an in vitro studyMaria Beatrice Morelli, Andrea Spinaci, Cui Chang, et al.
Molecular Diagnosis & Therapy|March 30, 2016
Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate CancerVincenza Conteduca, Simon J Crabb, Emanuela Scarpi, et al.
Scientific Reports|October 20, 2018
Plasma androgen receptor and serum chromogranin A in advanced prostate cancerVincenza Conteduca, Emanuela Scarpi, Samanta Salvi, et al.
World Journal of Urology|October 9, 2025
The prostatic inflammation score and risk of biochemical recurrence following radical prostatectomyFrancesco Guzzi, Ugo Giovanni Falagario, Angelo Cormio, et al.
Frontiers in Oncology|October 19, 2020
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell TumorsGiuseppe Schepisi, Vincenza Conteduca, Chiara Casadei, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2019
Clinical features of neuroendocrine prostate cancerVincenza Conteduca, Clara Oromendia, Kenneth W Eng, et al.
The Prostate|April 22, 2017
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abirateroneVincenza Conteduca, Orazio Caffo, Cristian Lolli, et al.
Plos One|July 20, 2016
Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate CancerVincenza Conteduca, Simon J Crabb, Robert J Jones, et al.
Oncotarget|July 14, 2016
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinibCristian Lolli, Umberto Basso, Lisa Derosa, et al.
Pageof 16